We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Gen5™ v1.02 Provides Enhanced Curve Fit Methods for BioTek's Microplate Readers

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

BioTek Instruments has announced the release of Gen5™ Microplate Data Analysis Software, version 1.02. This latest version provides new data reduction tools, including a 5-parameter logistic fit, several weighting options and curve constraint definition.

New curve metrics include 95% confidence intervals, sum of squares and degrees of freedom for more detailed results.

Several new experiment and protocol files have been added to the extensive sample files already available in Gen5. Protocols for critical assays such as AlphaScreen cAMP™, MycoAlert® and IC50 can be opened and modified as necessary for rapid analyses with minimal setup.

Custom summary results and/or detailed procedure and data reduction steps may be quickly printed or exported for one-step documentation of all experimental parameters.

As the powerful operating system for all of BioTek's microplate readers, Gen5 v1.02 software offers a clean and uncluttered interface with multiple options for access to the most common tasks.

With increased speed, accuracy and power, Gen5 v1.02 maintains flexibility for the unique requirements and preferences of microplate instrumentation users.

Gen5 v1.02 includes StepWise™ tools that provide intuitive and rapid protocol creation, access and execution for basic to very complicated protocols.

Gen5 v1.02 is compatible with the new Windows Vista™ operating system and is available in several editions to meet any laboratory's needs, including Gen5 Secure with features necessary for compliance to 21 CFR Part 11.